About this research
In collaboration with a committee of industry experts in real world evidence, the PAAB has created a Real-World Evidence (RWE) guidance document (view here) aimed at facilitating the delivery of current RWE data to HCPs to help inform healthcare decision-making.
About PAAB:
The Pharmaceutical Advertising Advisory Board (PAAB) is an independent and not-for-profit organization. It is the only preclearance agency that is recognized by Health Canada for the review of advertising directed to health professionals. PAAB works to protect Canadians by ensuring that drug advertising directed to health professionals meets the regulatory, scientific, therapeutic, and ethical standards outlined in the Code of Advertising Acceptance. All PAAB approved materials bear the PAAB logo. The PAAB logo provides assurance that the information you receive has undergone independent review.
Why PAAB created this draft:
In a perfect world, all clinical decisions would be supported by gold-standard evidence. However, in the real world, many clinical questions have yet to be studied in high-quality RCTs and we recognize that there is potentially valuable information available in RWE. Real world evidence can be incorporated into advertising in a way that can help you discover what current data is available while also informing you of their key limitations so that, should you find it useful or interesting, you can explore the source further
Nothing will change for data presentations that are based on evidence which meets the PAAB’s existing standards for clinical trials (e.g., controlled, and well-designed trials with an acceptable level of statistical significance). Data presentations based on RWE will be handled differently.
Why PAAB needs your feedback:
Our approach to RWE seeks to ensure that there is adequate transparency with regards to not only their potential usefulness, but also their limitations, and that, unlike messaging based on gold-standard evidence, such data is presented in a neutral and non-promotional manner.
To this end, we would like to get your feedback to ensure that our approach to the presentation of RWE in advertising is of value to you and your practice.
Who should apply to complete this survey?
Canadian-based healthcare professionals who engage with pharmaceutical representatives, receive pharmaceutical product advertising and support materials, and prescribe medications to patients. If you meet this criteria, please read below.
About PAAB:
The Pharmaceutical Advertising Advisory Board (PAAB) is an independent and not-for-profit organization. It is the only preclearance agency that is recognized by Health Canada for the review of advertising directed to health professionals. PAAB works to protect Canadians by ensuring that drug advertising directed to health professionals meets the regulatory, scientific, therapeutic, and ethical standards outlined in the Code of Advertising Acceptance. All PAAB approved materials bear the PAAB logo. The PAAB logo provides assurance that the information you receive has undergone independent review.
Why PAAB created this draft:
In a perfect world, all clinical decisions would be supported by gold-standard evidence. However, in the real world, many clinical questions have yet to be studied in high-quality RCTs and we recognize that there is potentially valuable information available in RWE. Real world evidence can be incorporated into advertising in a way that can help you discover what current data is available while also informing you of their key limitations so that, should you find it useful or interesting, you can explore the source further
Nothing will change for data presentations that are based on evidence which meets the PAAB’s existing standards for clinical trials (e.g., controlled, and well-designed trials with an acceptable level of statistical significance). Data presentations based on RWE will be handled differently.
Why PAAB needs your feedback:
Our approach to RWE seeks to ensure that there is adequate transparency with regards to not only their potential usefulness, but also their limitations, and that, unlike messaging based on gold-standard evidence, such data is presented in a neutral and non-promotional manner.
To this end, we would like to get your feedback to ensure that our approach to the presentation of RWE in advertising is of value to you and your practice.
Who should apply to complete this survey?
Canadian-based healthcare professionals who engage with pharmaceutical representatives, receive pharmaceutical product advertising and support materials, and prescribe medications to patients. If you meet this criteria, please read below.
|
What you need to doTo contribute to this online survey, you need to pass a short screener at the bottom of this page. (note. you will NOT be reimbursed for completing the screener).
If you are invited to complete the full online survey, you will be asked to review a short document on Real World Evidence before you start. You do not need to download any software to complete this survey. At no time will we ask you to install any software. |
|
Time and reimbursementThe survey may take you up to 20 minutes to complete, this includes the time to review supporting documentation.
This survey and its associated honoraria is only available to the 1st 100 people. You will be informed after a small screener if you've been accepted to the full survey. Once you complete all questions of the online survey you'll be offered $100 CAD honorarium for your services in the form of a digital Visa card, or, Amazon gift card. |
|
Data we collect from you If you choose to contribute to this survey, the Data we collect from you will be used for the purposes of administering this survey, and future surveys that PAAB may invite you to be part of.
You can remove your Personal and Response Data at any time by emailing info@paabtraining.ca. You can view our Privacy Notice by clicking here. |
Ready to complete the screener?
Below is a short screener to determine if you're suitable for this research. You will not be paid for completing this screener and your data will not be stored unless you provide consent at the end.
